At the West Michigan Rheumatology we pride ourselves in bringing patient centered, and research inspired care to West Michigan. Our rheumatology specialists work to understand your needs and circumstances in order to craft a treatment plan that helps place you in control. By focusing on both clinical services and research in one location, we’re making innovative rheumatic therapies within reach of West Michigan and the Lakeshore
National News: June 2014 Research conducted at West Michigan Rheumatology was published on June 12, 2014 in the prestigious New England Journal of Medicine. 9 patients from West Michigan participated and contributed to the success of this landmark study of psoriatic arthritis. However the ground work began with the planning a series of studies in rheumatoid arthritis beginning in October of 2008. Over twenty West Michigan volunteers participated in 3 studies that helped researchers understand the biologic effects of brodalumab. This has lead to the advancement of brodalumab as potentially leading therapy for psoriatic arthritis. Thank you!
Local Impact: Psoriatic arthritis is a relatively common form of inflammatory arthritis that effects approximately 4000 people in the greater Grand Rapids area. It can be a hereditary disease, as about 40% of people with psoriatic arthritis have a famiy member with psoriasis or psoriatic arthritis. It typically presents as joint and tendon swelling with or without low back stiffness from sacroilitis. The joints become swollen and have stiffness that is worse in the morning, that improve over 1-2 hours after arising. Nail pitting is present in about 80% of patients with psoriatic arthritis.
The disease varies from mild, requiring only NSAIDs like naproxen, to very severe causing deforming joint damage. Treatment of psoriasis plus other FDA approved immune modulators like TNF inhibitors (for more information see patient decision aid) may be needed to control the skin and joint inflammation.
Brodalumad represents a promising new targeted treatment for psoriatic arthritis.
Learn more about the current phase 3 study now being conducted of brodalumab at WMR.